Patients with type 2 diabetes have a lower TBS than non-diabetic individuals, suggesting that TBS can be a useful measurement for the assessment of fracture risk in diabetic patients (Osteoporosis International)
Diabetes News
Glycosmedia is dedicated to bringing free, non-promotional, editorially independent news to a global audience about developments in diabetes, and is primarily aimed at health professionals.
Effect of dipeptidyl-peptidase-4 inhibitors on C-reactive protein in patients with type 2 diabetes: a systematic review and meta-analysis
DDP-4i effectively reduced serum CRP levels and showed no stronger effect than traditional oral antidiabetic agents (Lipids in Health and Disease)
SGLT inhibitors: medications that mimic fasting for cardiovascular prevention
This review proposes a unifying hypothesis to explain the reduction in cardiovascular diseases through three different mechanisms of curbing free fatty acid (FFA) excess, all leading to the common mechanism of cellular caloric restriction. If this hypothesis is correct, the excellent results obtained with SGLT‐2 inhibitors could be attributed to their close simulation of fasting (Diabetes, Obesity and Metabolism)
SGLT2 inhibitors in T2D and associated comorbidities — differentiating within the class
Cardiovascular outcomes trials investigating SGLT2 inhibitors have suggested benefits beyond glucose lowering that have been confirmed in real-world evidence studies (BMC Endocrine Disorders)
Association between insulin resistance and haematological parameters: a cohort study from adolescence to adulthood
Both longitudinal and cross‐sectional analyses support the hypothesis that insulin resistance is associated with increased red blood cells count and haematocrit in young adults, even within normal ranges of insulin and glucose (Diabetes/Metabolism Research and Reviews)
Deintensification in older patients with type 2 diabetes: A systematic review of approaches, rates and outcomes
Available but limited evidence suggests that the benefits of deintensification outweigh the harm in older people with type 2 diabetes with or without comorbidities (Diabetes, Obesity and Metabolism)
Lower Renal Threshold for Glucose Reabsorption in Type 1 Diabetes Mellitus (T1DM) May Explain the Smaller Contribution of SGLT2 Inhibitors to the Improvement of Plasma Glucose Control Compared with T2DM
These results indicate that it is advisable to estimate the renal threshold for glucose reabsorption prior to initiating SGLT2 inhibitor therapy in patients with T1DM (Diabetes Therapy)
Cardiovascular Risk and Risk Factor Management in Type 2 Diabetes Mellitus
Compared with men developing T2DM, women with T2DM do not have a significantly higher relative increase in cardiovascular risk, but ongoing sex disparities in prescribing should prompt heightened efforts to improve the standard and equity of diabetes mellitus care in women and men (Circulation)
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years (NEJM)
Early Glomerular Hyperfiltration and Long-Term Kidney Outcomes in Type 1 Diabetes
Early hyperfiltration in patients with type 1 diabetes was not associated with a higher long-term risk of decreased GFR. Although glomerular hypertension may be a mechanism of kidney injury in DKD, higher total GFR does not appear to be a risk factor for advanced DKD (Clinical Journal of the American Society of Nephrology)
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
In this trial involving patients with type 2 diabetes, the cardiovascular risk profile of oral semaglutide was not inferior to that of placebo (NEJM)
Lack of Durable Improvements in β-Cell Function Following Withdrawal of Pharmacological Interventions in Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes
In adults with IGT or recently diagnosed type 2 diabetes, interventions that improved β-cell function during active treatment failed to produce persistent benefits after treatment withdrawal. These observations suggest that continued intervention may be required to alter the progressive β-cell dysfunction in IGT or early type 2 diabetes (Diabetes Care)
An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes
Teplizumab delayed progression to clinical type 1 diabetes in high-risk participants (NEJM)
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
Dulaglutide could be considered for the management of glycaemic control in middle-aged and older people with type 2 diabetes with either previous cardiovascular disease or cardiovascular risk factors (Lancet)
Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial
Dapagliflozin seemed to prevent and reduce progression of kidney disease compared with placebo inthis large and diverse population of patients with type 2 diabetes with and without established atheroscleroticcardiovascular disease, most of whom had preserved renal function (Lancet)
Utilizing the Ambulatory Glucose Profile to Standardize and Implement Continuous Glucose Monitoring in Clinical Practice
We describe the core CGM metrics, as well as the standardized glucose profile format consolidating 2 weeks of CGM measurements, referred to as the ambulatory glucose profile (AGP), which was also recommended by the CGM expert pane (Diabetes Technology and Therapeutics)
Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes
In this post hoc analysis of SUSTAIN 6, once-weekly semaglutide vs placebo reduced the risk of MACE in all subjects included in the trial, regardless of gender, age, or baseline CV risk profile (Cardiovascular Diabetology)
Intensive Glucose Control in Patients with Type 2 Diabetes — 15-Year Follow-up
Participants with type 2 diabetes who had been randomly assigned to intensive glucose control for 5.6 years had a lower risk of cardiovascular events than those who received standard therapy only during the prolonged period in which the glycated hemoglobin curves were separated (NEJM)
Modelling potential cost savings from use of real‐time continuous glucose monitoring in pregnant women with Type 1 diabetes
Routine use of RT‐CGM by pregnant women with type 1 diabetes, would result in substantial cost savings, mainly through reductions in NICU admissions and shorter duration of NICU care (Diabetes Medicine)
Diabetic foot ulcer incidence and survival with improved diabetic foot services: an 18‐year study
Integrated care for the diabetic foot in one National Health Service (NHS) health service area over 18 years was associated with a reduction in first presentations of diabetic foot ulceration, but failed to reduce recurrent ulceration. Cumulative prevalence of all ulcers continues to increase (Diabetic Medicine)
- 1
- 2
- 3
- …
- 181
- Next Page »
Glycosmedia is also available as an App: